Cellectar chief Clarke will be on board
By KATHLEEN GALLAGHER
Posted: Feb. 22, 2007
A little more than two years ago, William Clarke was telling more than 300 people at the state biotech association's annual meeting about Wisconsin's potential to help "design and weave" the dramatic changes on the horizon for medicine.
Now the man who oversaw technology development at GE Healthcare has thrown himself into the front lines of the young Madison companies aiming to make those changes happen.
Clarke in December left his position as chief technology officer and chief medical officer at GE Healthcare to run Cellectar LLC, a company aiming to bring to market drug-based radiation treatments that it believes will kill cancer tumors.
Caden Biosciences Inc., another Madison company, said Thursday that Clarke, who is 55, has joined its board of directors. Caden is developing screening tools to sell to pharmaceutical and biotech companies to help identify new drugs for a variety of diseases.
Clarke's move signals that Madison is becoming the kind of biotech center that can attract high-caliber managers.